vegfr fgfr inhibitor odm 203

Drug Overview

ODM-203 is an innovative, highly specialized medication designed to fight cancer by cutting off a tumor’s food and oxygen supply. It belongs to a modern group of medicines known as Targeted Therapy vegfr fgfr inhibitor odm 203. Unlike traditional chemotherapy that attacks all fast-growing cells in the body, this Smart Drug is designed to find and block specific “broken” signals that cancer cells rely on to survive and grow.

• Generic Name: ODM-203 (Investigational compound)
• US Brand Names: None (Currently an Investigational Drug)
• Drug Class: Dual VEGFR and FGFR Tyrosine Kinase Inhibitor (TKI); Angiogenesis Inhibitor
• Route of Administration: Oral (Tablet)
• FDA Approval Status: Investigational. It is currently being studied in clinical trials and has not yet been approved by the FDA for general public use.

What Is It and How Does It Work? (Mechanism of Action)

ODM-203 is a Smart Drug designed to stop a process called angiogenesis, which is how the body builds new blood vessels. Tumors need a constant blood supply to get oxygen and nutrients. If they cannot build new blood vessels, they starve and shrink.

The Problem with Single Targets

To build new blood vessels, tumors send out a chemical “help signal” that attaches to receivers on blood vessel cells called VEGFR (Vascular Endothelial Growth Factor Receptors). When doctors use drugs to block VEGFR, the tumor often cleverly switches to a backup plan. It starts using a different receiver called FGFR (Fibroblast Growth Factor Receptor) to keep growing its blood supply.

Dual Molecular Blocking

At the molecular level, ODM-203 is unique because it blocks both VEGFR and FGFR at the same time.

• The Blockade: The drug enters the cancer cells and attaches itself directly to the “engine” (the ATP-binding pocket) of both the VEGFR and FGFR receptors.
• Stopping the Signal: By locking into these pockets, ODM-203 shuts down the internal signaling pathways (specifically the MAPK and PI3K/AKT pathways). The receptors can no longer send messages to the cell’s center telling it to divide.
• Immune Boosting: Recent studies show ODM-203 also acts like a mild form of Immunotherapy. It lowers the “stop signals” (like PD-1 and PD-L1) on the tumor, helping to wake up the body’s own immune system (CD8+ T-cells) so it can better recognize and attack the cancer.

FDA Approved Clinical Indications

Because ODM-203 is an investigational drug, it does not currently have standard FDA-approved uses. It is only available to patients participating in approved clinical trials.

• Oncological Uses (In Clinical Trials):
  • Advanced solid tumors with specific FGFR genetic changes.
  • Advanced or metastatic Bladder Cancer (Urothelial Carcinoma) in patients with FGFR3 mutations.
  • Advanced Kidney Cancer (Renal Cell Carcinoma).
• Non-oncological Uses:
  • There are currently no non-cancer uses for this medication.

Dosage and Administration Protocols

Because it is an experimental drug, the dosage depends strictly on the specific clinical trial protocol. It is taken by mouth, which offers a convenient alternative to hospital IV drips.

Dose Adjustments:

• Hepatic (Liver) Insufficiency: ODM-203 heavily affects how the liver processes a substance called bilirubin (by inhibiting an enzyme called UGT1A1). If liver blood tests show that bilirubin is getting too high, the dose must be reduced or paused to protect the liver.
• Renal (Kidney) Insufficiency: Mild kidney issues generally do not require a dose change, but kidney health is monitored closely.

Clinical Efficacy and Research Results

Recent clinical research from 2020 to 2025 has provided valuable data on how well ODM-203 works, particularly from Phase I/IIa clinical trials.

• Overall Response Rate (ORR): In a recent clinical trial evaluating the 400 mg daily dose in patients with advanced solid tumors, the drug showed an ORR of 9.2%, meaning nearly 1 in 10 patients saw their tumors shrink significantly.
• Progression-Free Survival (PFS): The drug was highly effective at keeping the cancer from growing. Patients whose tumors had specific FGFR genetic mutations experienced a median PFS of 16.1 weeks. Patients without these specific mutations had a median PFS of 12.4 weeks.
• Time on Treatment: Patients were able to stay on the 400 mg tablet dose for a median of 14.5 weeks, showing that the drug can provide stable disease control for several months in heavily pre-treated patients.

Safety Profile and Side Effects

Important Safety Note: Because ODM-203 is an investigational drug, it does not currently carry an official FDA “Black Box Warning.” However, clinical trials require strict monitoring for liver stress (high bilirubin) and potential vision changes.

Common Side Effects (>10%)

• Hyperbilirubinemia: High levels of bilirubin causing jaundice (mild yellowing of the skin and eyes). This affects up to 75% of patients taking the drug.
• Diarrhea: Experienced by roughly 50% of patients.
• Alopecia: Temporary hair thinning or hair loss.
• Stomatitis: Soreness, redness, or small ulcers in the mouth.

Serious Adverse Events

• Severe Liver Toxicity: Extremely high bilirubin or liver enzymes that can damage the liver.
• Corneal Keratopathy: Clouding or damage to the clear front part of the eye, which can affect vision.
• Electrolyte Imbalance: Changes in blood calcium, magnesium, and phosphate levels.

Management Strategies

• Bilirubin Monitoring: Your doctor will run frequent blood tests. If bilirubin levels spike, the drug dose will be temporarily lowered to allow your liver to catch up.
• Eye Exams: Patients are often required to see an eye doctor (ophthalmologist) before starting the drug and regularly during treatment to catch any early signs of eye irritation.
• Anti-Diarrhea Medicine: Your medical team may prescribe medications to manage diarrhea and prevent dehydration.

Research Areas

ODM-203 is currently a major focus in Tumor Microenvironment research. By blocking both blood vessel growth and tissue growth signals, scientists are studying how ODM-203 can effectively “remodel” the tough outer shield of a tumor. Researchers are heavily investigating combining ODM-203 with standard Immunotherapy (immune checkpoint inhibitors). The theory is that once ODM-203 weakens the tumor’s defenses and blood supply, the immune system can step in and regenerate a healthy, cancer-free environment much more effectively.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Genetic Testing: Your doctor will test your tumor for FGFR3 mutations and test your blood for the UGT1A1 gene to ensure your body can safely process the drug.
• Liver Function Panel: To establish a healthy baseline for your liver enzymes and bilirubin.
• Ophthalmic Exam: A thorough eye checkup to ensure your corneas are healthy.
• Heart Check (ECG): To ensure normal electrical activity in your heart.

Precautions During Treatment

• Food Timing: The drug is absorbed best when taken with food. Follow your oncology team’s exact instructions regarding meals.
• Sun Protection: Some targeted therapies can make your skin more sensitive to sunlight.

“Do’s and Don’ts” list

• DO take the pill at the same time every day with food.
• DO check your skin and the whites of your eyes daily in the mirror. If you notice a yellow tint, call your doctor right away.
• DO report any blurry vision, dry eyes, or eye pain immediately.
• DON’T take any over-the-counter herbal supplements or new medicines without asking your pharmacist or oncologist, as they can interfere with how your liver handles the drug.
• DON’T skip your weekly or monthly blood test appointments. These tests catch side effects before you even feel them.

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. ODM-203 is an investigational medication and is only available to patients participating in approved clinical trials. Always consult your oncologist or licensed healthcare provider regarding your specific medical condition and treatment options. Individual results and side effects from clinical trials may vary.